Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

skinbetter science

Also known as: skinbetter, skin better science, skinbetter science, Skinbetter

A US professional-channel cosmetic skincare brand founded in 2016 and owned by L'Oreal since its 2022 acquisition agreement, sold in the UK through authorised clinics. Its signature ingredient is ethyl lactyl retinoate, an ester joining a retinoid to lactic acid, marketed as AlphaRet.

Evidence status

Manufacturer-supported

AlphaRet has one 48-woman split-face active comparison reporting selected non-inferiority findings versus 0.025% tretinoin and less erythema than 1% retinol. Other product studies are small and open-label, and every located study involved company employees or company funding; the 2019 pigment paper names an unnamed cream, so identification with Even Tone is inferred. No independent replication or head-to-head brand trial was located.

What skinbetter science is, and the ranges available#

skinbetter science is a professional-channel cosmetic skincare brand co-founded in Arizona in 2016 by Jonah Shacknai, Justin Smith and Seth Rodner. L'Oréal announced an agreement to acquire it in September 2022 for the Dermatological Beauty division. By 2024 authors were publishing under the affiliation “skinbetter science, a Dermatological Beauty brand of L'Oréal USA”.[8, 5][8, 5]

At acquisition, L'Oréal reported sales of nearly US$95 million in the preceding twelve months, mainly through US dermatology, plastic-surgery and medical-aesthetic practices. This is corporate scale, not a clinical outcome.[8]

No UK company named skinbetter was found at Companies House. The UK range is supplied through authorised clinics and professional stockists, some of which also sell online after clinic or consultation registration. On 2 August 2026 one authorised stockist listed AlphaRet Overnight Cream at £142 and Even Tone Correcting Serum 50 ml at £166.50.[12][12]

AlphaRet is the brand name for formulas using ethyl lactyl retinoate, CAS 74534-80-8, an ester of retinoic acid and ethyl lactate. The molecule predates the brand: it appeared in 2015 and 2016 commercial clinical papers and in a competitor patent as a catalogued third-party material. The proprietary object is the skinbetter formulation and trade name, not the existence of the molecule.[2, 3, 12]

AlphaRet Overnight Cream contains no retinol or retinyl ester. Its free hydroxy acid in the UK-listed formula is glycolic acid with sodium glycolate; lactic acid is bound within the conjugate.[12]

Use of skinbetter science in aesthetic practice#

The entire GB skinbetter range is cosmetic. It falls under assimilated Regulation (EC) No 1223/2009, with a UK Responsible Person, Product Information File, safety assessment and SCPN notification. It is not regulated as a medicine or medical device, so UKCA marking and MHRA device registration are not applicable credentials.[10, 11]

GB Annex II prohibits tretinoin, retinoic acid and its salts in cosmetics. Ethyl lactyl retinoate is an ester with its own INCI name and CAS number rather than tretinoin or a salt. No public record was located showing that a GB regulator has formally tested that distinction.[10, 12]

The EU has capped retinol, retinyl acetate and retinyl palmitate at 0.05% retinol equivalent in body lotion and 0.3% in other leave-on and rinse-off products, with market deadlines from November 2025 and May 2027. Great Britain had not adopted that restriction by 2 August 2026. Even if copied word for word, those three named substances do not include ethyl lactyl retinoate. Northern Ireland's position was not verified and needs separate checking.[11][9][9, 12]

A different EU restriction may be relevant to Even Tone Correcting Serum: its first declared active is alpha-arbutin, which EU rules cap at 2% in face cream and 0.5% in body lotion. The serum concentration is undisclosed and the product category is not self-evident; GB had no equivalent cap at the research date.[9, 12, 11]i

Professional-channel sale does not change these products into prescriptions or give the brand's training statutory status. The current Responsible Person on the UK pack is the reliable identity for product compliance.

Contraindications and cautions#

skinbetter is a portfolio rather than one active. Contraindications depend on the exact product, full ingredient list, intended site, concurrent prescription or cosmetic regimen, barrier condition and planned procedure. The current UK instructions govern.

AlphaRet products require particular care where a client already uses a prescription or cosmetic retinoid, has limiting irritation or is considering a procedure whose manufacturer specifies a retinoid stop period. Ethyl lactyl retinoate should not be treated as ordinary retinol, but neither should its proprietary name obscure that it is designed to release retinoid activity.[1, 2, 12]

Even Tone Correcting Serum uses a different active system, including alpha-arbutin, hexylresorcinol, diglucosyl gallic acid, acetyl glycyl beta-alanine and arginine PCA. Evidence and cautions for AlphaRet do not transfer to it.[12, 4]i

No pregnancy or reproductive-toxicity study of ethyl lactyl retinoate was located.[no source found]

Ethyl lactyl retinoate is an ester of retinoic acid and ethyl lactate. AlphaRet therefore should not be described as proven safe in pregnancy or breastfeeding; the current product instructions and an appropriately qualified clinician should govern product-specific maternity decisions. This precaution is not a quantified risk estimate.[12]

Where formulations have changed, the current pack supersedes an older study description. It is not established that the present UK Even Tone “b.r.y.t.” formula is identical to the product assessed in 2019.[4, 12]

Clinical uses and the evidence behind them#

AlphaRet for photodamage

The strongest skinbetter study was a 12-week randomised split-face comparison in 48 women aged 30–65 with mild-to-severe photodamage. Twenty-four compared AlphaRet with 1% retinol and 24 with 0.025% tretinoin. Blinded expert grading reported AlphaRet non-inferior to tretinoin across all categories at weeks four and eight, and for fine lines and wrinkles, erythema, dyschromia and tone at week 12. AlphaRet produced less erythema than 1% retinol at weeks eight and 12.[1]

This is a meaningful comparative finding with a narrow scope. The comparator was the lowest marketed tretinoin strength, there were 24 participants per comparison, no vehicle or untreated control, one site, women only and 12 weeks of observation. Two of four authors worked for the manufacturer and no independent replication was located.[1]

Even Tone Correcting Serum

A 2019 paper studied an unnamed non-hydroquinone skin-tone-correcting cream; it does not name Even Tone Correcting Serum and calls the product a cream, not a serum. Connecting that study to Even Tone is an inference from the initialism, company authorship and current brand context. In 42 participants it reported significant reductions from baseline in dyschromia and Melanin Index over 12 weeks, sustained to 16 weeks; a separate non-randomised group of ten used the cream with a retinoid/AHA product, without a reported between-group test.[4, 12]i

There was no hydroquinone or other active comparator. “Non-hydroquinone” accurately describes the formulation; “hydroquinone alternative” as an equivalent clinical result is not established. It is also unclear whether the present UK formula is the one studied.[12][4]

Blemish-prone, neck and darker-phototype studies

The remaining product programme consists mainly of open-label work: 20 participants for blemish-prone skin, 26 plus ten for a neck cream, 21 in a Fitzpatrick IV–V regimen and a small darker-skin pilot without a stated total in the indexed record. Investigator appearance grading and absence of a control limit causal interpretation.[4, 5, 6, 7, 13]

The Fitzpatrick IV–V study used an antioxidant serum, AlphaRet and SPF 56 in 21 women aged 40–65. At 12 weeks it reported improvements in dullness, texture, tone, erythema and melanin, with no adverse-event discontinuations. The multi-product regimen prevents attribution to AlphaRet alone.[5]

All six located skinbetter clinical studies included Mitchell Wortzman, Diane Nelson or both as company employees; two 2024 papers list skinbetter science LLC as funder. Commercial involvement does not invalidate the observations, but it travels with them.[1, 4, 5, 6, 7, 13]

Selecting a skinbetter science product#

Selection matches the exact finished formula to the concern and the strength of the product-specific evidence. AlphaRet has one randomised active comparison for appearance endpoints in photodamage; Even Tone has uncontrolled before-and-after data; other systems have small open-label studies. Ingredient mechanisms do not upgrade those designs.

The current UK ingredient list should be compared with the studied formulation. Ethyl lactyl retinoate concentration in AlphaRet is not disclosed, and published 0.1% concentrations belong to older products from other companies. Even Tone's current “b.r.y.t.” identity may differ from the 2019 study product.[2, 3, 4, 12]

Product cost, channel support and tolerability may influence selection, but no independent study establishes clinical superiority over another professional brand. A tolerated cosmetic formulation can still be useful without being represented as equivalent to a prescription retinoid.

The current manufacturer directions govern application, frequency, combination and procedure timing. Skinipedia does not publish a generic AlphaRet or pigment-serum protocol.

Adverse effects and their management#

Irritation and erythema

Retinoid- and acid-containing formulas may produce dryness, stinging, erythema or peeling. In the head-to-head trial, AlphaRet produced less erythema than 1% retinol at weeks eight and 12; that comparative tolerability result applies to the studied formulas and population, not every product in the range.[1]

Pigment and blemish regimens

The darker-phototype study reported no discontinuations for adverse events, but it enrolled 21 women, used several products and ended at 12 weeks. That sample cannot exclude uncommon reactions or establish safety for all phototypes and conditions.[5]

Persistent or unexpected reactions

Escalating inflammation, blistering, extensive desquamation, pigment change, suspected allergy or a reaction that fails to settle after the product is stopped requires assessment under the exact product directions. The named product, lot, ingredient list, concurrent products and timing should remain in the record.

Referral and scope boundaries#

skinbetter cosmetics do not treat a medical diagnosis by regulatory status. Moderate or severe acne, scarring acne, unexplained or changing pigmentation, suspected dermatitis, infection or another presentation requiring diagnosis is referred to an appropriate clinician.

Prescription tretinoin remains a prescriber's decision. The AlphaRet comparison does not authorise substitution for a prescription plan or imply equivalence for acne, histology or higher tretinoin strengths.[1]

Product reactions requiring medical treatment, eye involvement, extensive swelling, systemic symptoms or progressive pigment change also sit outside routine cosmetic management.

Mechanism of action#

Ethyl lactyl retinoate is designed to hydrolyse in skin and release a retinoid component and lactic acid. AlphaRet finished formulas may also contain glycolic acid and other actives. No human pharmacokinetic study was located establishing how much retinoic acid is liberated or over what time course.[2, 12]

Even Tone uses a separate group of pigment-directed ingredients. The evidence for retinoids, glycolic acid, lactic acid, alpha-arbutin and hexylresorcinol belongs to the relevant ingredient evidence; the brand evidence asks whether the complete skinbetter formula was tested.

Commonly misstated claims#

“L'Oréal acquired skinbetter in 2024”

L'Oréal's acquisition agreement was announced on 23 September 2022, and by early 2024 company papers already described skinbetter as a L'Oréal brand.[5, 8]

Supported statement: skinbetter has belonged within L'Oréal Dermatological Beauty since the 2022 transaction.

“AlphaRet is a unique molecule available only from skinbetter”

Ethyl lactyl retinoate was published in commercial products before skinbetter existed and appears as a catalogued raw material in patent literature.[2, 3, 12]

Supported statement: AlphaRet is skinbetter's proprietary formulation and trade name for products built around ethyl lactyl retinoate.

“AlphaRet is as effective as prescription tretinoin”

One company-authored 12-week study reported selected non-inferiority findings against 0.025% tretinoin on investigator-graded photodamage endpoints. It did not establish equivalence to tretinoin as a class, for acne, histology or higher strengths.[1]

Supported statement: AlphaRet performed non-inferiorly to 0.025% tretinoin on most measured appearance endpoints in one small split-face trial.

“Even Tone is a proven hydroquinone alternative”

The 2019 paper had no hydroquinone or other comparator and did not name Even Tone; the product connection is inferred.[4, 12]

Supported statement: an unnamed company-studied tone-correcting cream reduced measured dyschromia from baseline in one uncontrolled study; whether that result transfers to current Even Tone is unconfirmed.

Areas of remaining uncertainty#

  • The concentration of ethyl lactyl retinoate is undisclosed; this prevents comparison with older 0.1% products or a dose-response claim.
  • It is not established that current UK AlphaRet and Even Tone formulations are identical to those studied; this limits direct transfer of trial results after reformulation.
  • Human conversion of the ester to retinoic acid has not been quantified publicly; this prevents a precise potency comparison with retinol or tretinoin.
  • Northern Ireland's application of the EU vitamin A and alpha-arbutin restrictions was not verified; this requires a separate jurisdictional check before supply advice.
  • No independent replication or systematic review of a skinbetter product was located; this leaves company-authored findings as the present evidence ceiling.[no source found]

Frequently asked questions#

Is AlphaRet retinol?

No. Its defining ingredient is ethyl lactyl retinoate, not retinol or a retinyl ester. The finished overnight cream also contains free glycolic acid.[2, 12]

Is AlphaRet equivalent to tretinoin?

One small trial reported selected non-inferiority findings against 0.025% tretinoin for photodamage appearance endpoints. That is narrower than general clinical equivalence.[1]

Are skinbetter products medicines or medical devices?

No. In GB the range is cosmetic and follows cosmetic-product law.[10, 11]

Does the EU retinol cap apply in Great Britain?

Not as at 2 August 2026. GB had not adopted it, and ethyl lactyl retinoate is not one of the three substances named in the EU vitamin A entry.[12][11, 9]

What application schedule applies?

The current directions for the exact UK product govern. Skinipedia does not publish a generic substitute.

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. McDaniel DH, Mazur C, Wortzman MS, Nelson DB. Efficacy and tolerability of a double-conjugated retinoid cream vs 1.0% retinol cream or 0.025% tretinoin cream in subjects with mild to severe photoaging. J Cosmet Dermatol. 2017 Dec;16(4):542-548. doi:10.1111/jocd.12381. PMID 28762645.Tier 2Supports: 12-week, split-face, randomised trial in 48 female subjects aged 30-65 with mild to severe photodamage; 47 completed. AlphaRet Overnight Cream (AHA-Ret) applied to one side of the face PM, with either 1.0% retinol (n=24) or 0.025% tretinoin (n=24) on the other side. Blinded expert evaluation of images plus Nova measurements at 4, 8 and 12 weeks. AHA-Ret gave significant reductions from baseline in fine lines/wrinkles (P<.001, all time points), erythema (P=.004 at 8 weeks, P<.0001 at 12), dyschromia (P<.0001, all time points), skin tone (P<.0001, all time points) and pore size (P=.035 at 8 weeks, P<.0001 at 12). AHA-Ret induced less erythema than retinol at 8 (P=.008) and 12 (P<.02) weeks. Verbatim: 'AHA-Ret was noninferior to prescription tretinoin in all categories at 4 and 8 weeks, and for Fine Lines/Wrinkles, Erythema, Dyschromia, and Skin Tone at 12 weeks.' Hydration improved with AHA-Ret only. SCOPE LIMITS: no vehicle or untreated control; only 24 subjects per comparator; comparator tretinoin was the lowest marketed strength (0.025%); single investigator site; female only; 12 weeks; non-inferiority margin not stated in the abstract; never independently replicated.Funding / interest: Two of the four authors (Wortzman MS, Nelson DB) list their affiliation as Skinbetter Science, Phoenix, AZ. No separate funding statement is carried in the PubMed record and the publisher full text could not be retrieved (HTTP 402). Treat as company-conducted.
  2. Katz BE, Lewis J, McHugh L, Pellegrino A, Popescu L. The Tolerability and Efficacy of a Three-product Anti-aging Treatment Regimen in Subjects with Moderate-to-severe Photodamage. J Clin Aesthet Dermatol. 2015 Oct;8(10):21-26. PMCID PMC4633208, PMID 26557215. ClinicalTrials.gov NCT02422836.Tier 3Supports: First published clinical study of the molecule. Open-label, 8 weeks, 25 women mean age 54.1 +/- 8.9 years (range 36-65) with moderate-to-severe photodamage, using a twice-daily cleanser (7.8% l-lactic acid, 2% salicylic acid) plus serum (0.1% AHA-retinoid conjugate, 6.5% l-lactic acid) with SPF 50+ as needed. Verified week-8 improvements, all p<0.001: photodamage 17.11%, dryness 46.51%, dyschromia 56.52%, stinging 76.19%, erythema 52.63%, global improvement 72.8%. Products well tolerated. Verbatim description of the molecule: 'Ethyl lactyl retinoate (AHA retinoid conjugate, or AHA-RC), is the first double conjugate retinoid to deliver both AHA and RC to skin on a hydrolysis-based time-released mechanism biologically designed to maximize efficiency and minimize potential irritation from the retinoid component.' LOAD-BEARING FOR PROVENANCE: this is 2015, before skinbetter science existed, and the products were not skinbetter's. SCOPE LIMITS: n=25, no control arm, 8 weeks, regimen not single product, so no endpoint here is attributable to the conjugate alone; the design also cannot separate treatment effect from regression to the mean or from the concurrent SPF 50+.Funding / interest: Verbatim disclosure: 'Dr. Katz is a paid independent research consultant for US Cosmeceutechs, LLC. Joseph Lewis and Laura McHugh are employees of US Cosmeceutechs, LLC, owner of pending patents for technologies used in this study. Arthur Pellegrino and Lativia Popescu are employed by Elizabeth Arden, Inc., an investor in US CosmeceuTechs, LLC.'
  3. Draelos Z, Lewis J, McHugh L, Pellegrino A, Popescu L. Novel retinoid ester in combination with salicylic acid for the treatment of acne. J Cosmet Dermatol. 2016 Mar;15(1):36-42. doi:10.1111/jocd.12190. PMID 26516077.Tier 3Supports: Open-label, 8-week, three-product regimen study in 27 women aged 20-58 (mean 37.81 +/- 10.04) with mild-to-moderate acne, using a twice-daily cleanser plus serum containing 0.1% AHA-RC, 2% salicylic acid and 10.4% l-lactic acid, with SPF 50+ as needed. Actual lesion-count results, which are stronger than a bare 'statistically significant' implies: at week 4, inflammatory lesions P=0.006 and non-inflammatory lesions P=0.015; by week 8, verbatim, 'highly significant (P < 0.001) reductions in both lesion counts'. Secondary endpoints (dryness, stinging) rated 0-5. This is the only study anywhere in this package that uses hard lesion counts rather than investigator appearance grading. SCOPE LIMITS: n=27, no control arm, 8 weeks, women only, effect cannot be attributed to the conjugate rather than to the salicylic and lactic acids in the same serum. Pre-dates skinbetter and is not a skinbetter product.Funding / interest: Authors Lewis, McHugh and Popescu list US CosmeceuTechs, LLC; Pellegrino and Popescu list Elizabeth Arden, Inc. Draelos is a paid clinical investigator. Commercially conducted.
  4. Grimes PE, McDaniel DH, Wortzman M, Nelson D. In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream. J Drugs Dermatol. 2019 Jul 1;18(7):642-648. PMID 31329402.Tier 3Supports: Twice-daily use of a non-hydroquinone skin tone corrector (ETCS) and of ETCS + AHA-Ret in subjects with mild to severe dyschromia, over 12 weeks with a 16-week extension. Significant mean reductions from baseline in dyschromia for ETCS (n=42) and ETCS + AHA-Ret (n=10), both P<0.0001. Melanin Index fell significantly at every timepoint (ETCS: P<0.0001; ETCS + AHA-Ret: P<0.02 at 4 weeks, P<0.0001 at 8 and 12 weeks). Reductions in dyschromia and MI sustained at 16 weeks (P<0.0001 each). Mild transient adverse events, no discontinuations. Authors' conclusion, verbatim: 'Combination use with a retinoid-based, AHA cream in the evening demonstrated enhanced reductions.' SCOPE LIMITS: no comparator arm of any kind - not hydroquinone, not vehicle; both arms received ETCS, so the study cannot separate ETCS from time, regression or sun avoidance. The combination subgroup is n=10 and there is no statement of randomisation between the two groups, so 'enhanced' is a between-group comparison in an uncontrolled study, and note that the combination arm's MI p-value at 4 weeks (P<0.02) was in fact WEAKER than monotherapy's (P<0.0001). The abstract does not state that the study was open-label, does not state the Fitzpatrick distribution, and does not report a formal between-group test. The in vitro component is cell-level and cannot support clinical claims. IDENTIFICATION CAVEAT: the paper's title and abstract say 'cream'/'skin tone corrector' and never name a commercial product; equating ETCS with the marketed Even Tone Correcting Serum is a reasonable inference from the initialism and the manufacturer authorship, not something the paper states.Funding / interest: Wortzman M and Nelson D were skinbetter science personnel at the time; Grimes and McDaniel are paid clinical investigators for the brand. Company-conducted.
  5. Grimes PE, Nelson DB. Evaluation of an advanced antioxidant and double-conjugated retinoid/AHA cream in participants with FST IV-V. J Cosmet Dermatol. 2024 Apr;23(4):1291-1297. doi:10.1111/jocd.16246. PMID 38406974.Tier 3Supports: Open-label, 12-week study. N=21 female participants, mean age 56 (range 40-65), Fitzpatrick IV and V equally represented (41% Hispanic, 36% African American, 32% Caucasian - these figures sum to 109% as published and should not be quoted as a clean breakdown), with mild-to-moderate facial photodamage. Regimen: twice-daily antioxidant serum plus nightly AlphaRet cream plus daily broad-spectrum SPF 56. Significant mean improvements from baseline in skin dullness, skin texture and skin tone (all p<0.0001), and significant mean reductions in erythema and melanin at week 12. Mild transient adverse events; no discontinuation due to an adverse event. SCOPE LIMITS: n=21, single arm, no control, three products plus daily sunscreen used together so the AlphaRet contribution is not isolable, investigator visual grading, female only, 12 weeks. The author affiliation is the first primary-source confirmation in the peer-reviewed record of L'Oreal ownership: 'Clinical, Medical & Scientific Affairs, skinbetter science, a Dermatological Beauty brand of L'Oreal USA, Phoenix, Arizona, USA.'Funding / interest: PubMed funding metadata names the agency as 'skinbetter science, LLC'. Copyright line: '© 2024 skinbetter science'. Co-author Nelson DB is employed by skinbetter science / L'Oreal USA.
  6. Hartman CL, Dyck RM, Nelson DB. A pilot study examining a double-conjugated, retinoid-based skincare regimen for darker, blemish-prone skin. J Cosmet Dermatol. 2024 Feb;23(2):496-501. doi:10.1111/jocd.16141. PMID 38158455.Tier 3Supports: Open-label pilot, 12 weeks, female participants with mild-to-moderate blemish-prone skin; 55% Fitzpatrick IV and 27% Fitzpatrick V. Regimen: exfoliating peel pads (double-conjugated retinoid plus glycolic, lactic and salicylic acids) 3x/week for 8 weeks then 2x/week for 4 weeks, plus nightly AlphaRet Clearing Serum (AHARet-SA), cleanser, mineral sunscreen and moisturiser. Mean improvement from baseline in skin clarity on the 5-point IGA: 14% at 4 weeks (p=0.04), rising to 52% at week 12 (p=0.004). 88% of participants reported improvement in appearance, texture and fewer blemishes. Mild transient adverse events. SCOPE LIMITS: explicitly labelled a pilot; total N not stated in the abstract; no control arm; six products used concurrently; investigator IGA plus self-report; no lesion counts.Funding / interest: PubMed funding metadata names the agency as 'skinbetter science, LLC'. Copyright line: '© 2023 Skinbetter Science, LLC'. Co-author Nelson DB is employed by skinbetter science.
  7. Robinson D, Friedmann D, Gordon J, Wortzman M, Nelson D. Efficacy and Tolerability of a Double-Conjugated Retinoid and Alpha Hydroxy Acid Cream in Subjects With Mild to Moderate Blemish-Prone Skin. J Drugs Dermatol. 2022 Jan 1;21(1):54-59. doi:10.36849/JDD.2022.6415. PMID 35005862.Tier 3Supports: 12-week open-label study; 20 subjects enrolled, 19 completed, mild/moderate blemish-prone skin. Mean percent improvement from baseline in skin clarity on the Investigators Global Assessment Scale: 43% at week 4 (P<.0001), 48% at week 8 (P<.0001), 50% at week 12 (P<.0001). Visible improvement in pores 33% at 4 weeks (P<.0001), 21% at 8 weeks (P=.04), 25% at 12 weeks (P=.0006). A secondary quantitative pore analysis in only 6 subjects showed 18% mean improvement at week 12. Adverse events mild and transient. SCOPE LIMITS: n=20, no control arm, no lesion counts, quantitative sub-analysis n=6, single formulation but no comparator retinoid or benzoyl peroxide.Funding / interest: Wortzman M and Nelson D were skinbetter science personnel. Company-conducted; no external funder identified.
  8. L'Oreal. Press release: 'L'Oreal signs an agreement to acquire Skinbetter Science, a physician-dispensed american skincare brand.' Clichy, 23 September 2022. Corroborated by the L'Oreal Dermatological Beauty Division brand listing, retrieved 2 August 2026.Tier 4Supports: Verbatim: 'Clichy, September 23, 2022 - L'Oreal signed an agreement to acquire Skinbetter Science, a physician-dispensed American skincare brand'. States the brand was 'co-founded in 2016 by pharmaceutical industry professionals, Jonah Shacknai, Justin Smith and Seth Rodner'; that products are 'mainly available through a network of leading dermatology, plastic surgery and medical aesthetics practices throughout the United States'; and that it 'recorded nearly USD 95 million of sales in the trailing-twelve-months that ended August 31, 2022'. Headquartered in Arizona; integrated under Christina Fair, President of the Active Cosmetics Division within L'Oreal USA. VERIFIED 2 August 2026: loreal.com's brand index lists Skinbetter Science in the Dermatological Beauty Division alongside La Roche-Posay, Vichy, CeraVe and SkinCeuticals - so the division has since been renamed from Active Cosmetics to Dermatological Beauty, and both names refer to the same division. SCOPE LIMIT: this is the signing announcement, not a completion announcement. It does, however, state that closing was expected in early Q4 2022 subject to regulatory approval and customary conditions, so the transaction was contemplated to complete in 2022, not 2024. No separate completion announcement was located.Funding / interest: Issued by L'Oreal, the acquiring company and current owner of the brand. Promotional corporate communication.
  9. Commission Regulation (EU) 2024/996 of 3 April 2024 amending Regulation (EC) No 1223/2009 as regards the use of Vitamin A, Alpha-Arbutin and Arbutin and certain substances with potential endocrine disrupting properties in cosmetic products. OJ L, 2024/996, 4.4.2024.Tier 1Supports: Adds Annex III entry 376 covering Retinol (CAS 11103-57-4/68-26-8), Retinyl Acetate (127-47-9) and Retinyl Palmitate (79-81-2): maximum (a) 0.05% Retinol Equivalent in body lotion, (b) 0.3% RE in other leave-on and rinse-off products, with obligatory labelling 'Contains Vitamin A. Consider your daily intake before use'. Transitional footnote (*3), verbatim: 'From 1 November 2025 cosmetic products containing that substance and not complying with the conditions shall not be placed on the Union market. From 1 May 2027 cosmetic products containing that substance and not complying with the conditions shall not be made available on the Union market.' Adds entries 377 Alpha-Arbutin (max 2% face cream, 0.5% body lotion) and 378 Arbutin (max 7% face cream), both under footnote (*2): not placed on the Union market from 1 February 2025, not made available from 1 November 2025. SCOPE LIMITS: this is EU law. It names only three vitamin A substances; ethyl lactyl retinoate is not among them. It has no effect in Great Britain.
  10. Regulation (EC) No 1223/2009 on cosmetic products, Annex II (list of substances prohibited in cosmetic products), as it forms part of assimilated law in Great Britain. legislation.gov.uk, retrieved 2 August 2026.Tier 1Supports: Annex II entry 375, verbatim: 'Tretinoin (INN) (retinoic acid and its salts)', CAS 302-79-4, EC 206-129-0 - prohibited in cosmetic products. This is the operative GB prohibition that separates a cosmetic retinoid from prescription tretinoin. SCOPE LIMIT: the entry covers retinoic acid 'and its salts'; it does not by its terms cover esters of retinoic acid. Ethyl lactyl retinoate is an ester, and carries its own INCI name and CAS number. Note also that the legislation.gov.uk revised text of the Annexes is only consolidated to 3 December 2020, so post-2020 GB amendments must be checked in the amending statutory instruments separately (see source 11).
  11. The Cosmetic Products Regulation (EC) No 1223/2009 (Restriction of Chemical Substances) (Amendment and Transitional Provisions) Regulations 2026 (SI 2026/23), and the other GB cosmetics restriction instruments made 2022-2026: SI 2022/659, SI 2023/764 (revoked), SI 2023/836, SI 2024/455, SI 2024/1334, SI 2025/413, SI 2025/901 and SI 2026/109.Tier 1Supports: Documentary negative, established by enumerating the legislation.gov.uk UK Statutory Instrument index for titles containing 'Cosmetic Products' and reading the GB cosmetics restriction instruments made between 2022 and 4 February 2026, text-searching each for 'Retinol', 'Retinyl', 'Vitamin A' and 'Arbutin': zero occurrences in any of them. CORRECTED COUNT: there are NINE such instruments in the window, not eight - an earlier draft omitted SI 2023/764, The Cosmetic Products (Restriction of Chemical Substances) Regulations 2023 (made 6 July 2023, since revoked), which restricts Methyl-N-methylanthranilate in Annex III and adds two Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine UV-filter entries to Annex VI, and likewise mentions none of the four search terms. Verified endpoints of the range: SI 2026/23 (made 12 January 2026, in force 15 July 2026, reg 2(3) 15 August 2026) prohibits 3-(4'-methylbenzylidene)-camphor, deletes UV filter entry 18 (Enzacamene), tightens the formaldehyde-releaser labelling threshold from '0,05' to '0.001', and adds 16 CMR category 1B/2 substances to Annex II; SI 2026/109 (made 4 February 2026, in force 15 August 2026, reg 2(2) 23 March 2027) adds 13 CMR substances to Annex II and hexyl salicylate to Annex III. All extend to England, Wales and Scotland only. CONCLUSION SUPPORTED: as at 2 August 2026 Great Britain has adopted no maximum concentration for retinol, retinyl esters, arbutin or alpha-arbutin in cosmetic products, and no 'Contains Vitamin A' warning requirement. SCOPE LIMIT: this is a search of instruments titled 'Cosmetic Products...'; an amendment made under some other title would not have been caught, and the index search cannot exclude a restriction introduced by primary legislation or by a differently-titled SI.
  12. Product and ingredient identity sources accessed 2 August 2026: full INCI listings for AlphaRet Overnight Cream and Even Tone Correcting Serum published by UK authorised stockists Skin65 (skin65.co.uk) and Andy Millward Skincare (andymillward-skincare.co.uk); INCIDecoder CosIng mirror entry for Ethyl Lactyl Retinoate; European patent application EP4026535A1 (Intercos S.p.A., Biodegradable copolymers for cosmetic use); Companies House records for 'skinbetter'.Tier 4Supports: Ingredient identity, verified: Ethyl Lactyl Retinoate, CAS 74534-80-8, chemical/IUPAC name 'Retinoic Acid, 2-Ethoxy-1-Methyl-2-Oxoethyl Ester', functions abrasive and skin conditioning. The IUPAC name confirms the chemistry independently: the 2-ethoxy-1-methyl-2-oxoethyl group is the ethyl lactate residue, so the molecule is retinoic acid esterified to ethyl lactate - NOT a retinyl ester (which would be an ester of retinol). EP4026535A1 (Intercos S.p.A., 'Biodegradable copolymers for cosmetic use', filed 5 May 2017, published 13 July 2022) lists it in a table of CTFA-dictionary lactic acid derivatives as 'Ethyl Lactyl Retinoate is the organic compound that conforms to the formula: Lactic Retinoic Double Conjugate Ester (Pharma Cosmetix Research L.L.C.)' - i.e. a catalogued raw material attributed to a named third-party supplier, in a document filed by a company unconnected to skinbetter. AlphaRet Overnight Cream UK INCI, verified in full at Skin65 on 2 August 2026, in order: 'Aqua/Water, Sodium Glycolate, Glycolic Acid, Cetearyl Olivate, Pentylene Glycol, Cyclopentasiloxane, Isohexadecane, Sorbitan Olivate, Tetrahexyldecyl Ascorbate, Glycerin, Ceresin, Glycol Palmitate, Butylene Glycol, Niacinamide, Squalane, Methyl Gluceth-20, Ethyl Lactyl Retinoate, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Ceramide NP, Hyaluronic Acid, Ubiquinone, Tocopherol, Bisabolol...' - no retinol, no retinyl ester. Even Tone Correcting Serum UK INCI, verified in full: 'Aqua/Water, C13-15 Alkane, Propanediol, Caprylic/Capric Triglyceride, Glyceryl Stearate Citrate, Linoleic Acid, Glycerin, Dimethicone, Alpha-Arbutin, Arginine PCA, Hydrolyzed Sodium Hyaluronate, Bisabolol, Cetearyl Alcohol, Acetyl Glycyl Beta-Alanine, Hexylresorcinol, Terminalia Ferdinandiana (Kakadu Plum) Fruit Extract, Artemisia Capillaris Flower Extract, Diglucosyl Gallic Acid, Pancratium Maritimum Extract...' - Alpha-Arbutin is the ninth listed ingredient and the FIRST declared active; no retinoid of any kind; page copy verbatim 'b.r.y.t. technology - an advanced, non-retinol system'. UK listed prices at Skin65 on 2 August 2026: AlphaRet Overnight Cream £142 (30 ml and 50 ml both showing unavailable), Even Tone Correcting Serum 50 ml £166.50; both gated, with the page directing new patients to 'book a free virtual consultation' and requiring 'REGISTER TO BUY NOW'. Companies House name search for 'skinbetter' returned 'No results found', zero results. SCOPE LIMITS: retailer-published INCI is not the same as the on-pack label and may lag reformulation; concentrations are not disclosed; INCIDecoder is a third-party mirror of CosIng, not CosIng itself, whose API could not be queried directly. The Andy Millward listing could not be re-fetched on 2 August 2026 (404), so the 'Clinic Only' second-stockist gating is not independently confirmed here and rests on Skin65 alone.Funding / interest: Two of the three ingredient sources are UK retailers with a direct commercial interest in selling the brand. The patent is a competitor's document. Treat the INCI order as indicative, not certified.
  13. Robinson DM, Kaufman J, Giannini A, Rahman SM, Wortzman M, Nelson DB. Evaluation of a Neck Cream Developed to Enhance Nitric Oxide Availability in Aging Skin. J Drugs Dermatol. 2023 Sep 1;22(9):881-886. doi:10.36849/JDD.7210. PMID 37683057.Tier 3Supports: ADDED IN VERIFICATION - this sixth skinbetter clinical study was missing from the original package and its omission understated the size of the company's published programme. Dual-centre, open-label, 12-week study in aging women with mild-to-moderate lines, wrinkles and photodamage. Group 1 (n=26) used the neck cream alone: wrinkles/lines 21% improvement (P=.007), skin texture 27% (P=.004), skin tone 26% (P=.003). Group 2 (n=10) used the neck cream plus AHA-Ret: 34% improvement in photodamaged skin of the decolletage (P=.01). SCOPE LIMITS: open-label, no control or comparator arm, n=26 and n=10, investigator appearance grading, women only, 12 weeks, neck and decolletage rather than face, and the same non-randomised two-group structure as the Even Tone study, so the combination result cannot be read as evidence that adding AlphaRet caused the difference. It does not change any conclusion in this entry: it is another company-authored, uncontrolled, open-label study, and it strengthens rather than weakens the claim that the whole published programme is of that character.Funding / interest: Author affiliations verified on the publisher's article page: Mitchell Wortzman PhD and Diane B. Nelson RN MPH are listed as skinbetter science, LLC, Phoenix, AZ. Deanne Mraz Robinson (Modern Dermatology / DMR Research / Yale, and Chief Medical Officer of Ideal Image - a commercial aesthetics chain, a disclosure worth naming), Joely Kaufman (Skin Research Institute), Alessia Giannini and Syed Minhaj Rahman (DMR Research). No explicit funding statement was retrievable from the publisher page; PubMed carries no funding agency field. Company-conducted.